Axsome Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2024 | $180.7M | $57.0M | $315.4M |
| FY2025 | $117.7M | $88.3M | $322.9M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2024 | $180.7M | $57.0M | $315.4M |
| FY2025 | $117.7M | $88.3M | $322.9M |